Major depressive disorder is a common illness that severely decreases psychosocial functioning. Due to the major limitations of current treatments including response failure, it is crucial to develop better therapy strategies. Evidence suggests that dopamine dysregulation might play a major role in major depressive disorder physiopathology.
Aims:
This study investigates whether the dopamine D1 receptor agonist A77636 modulates antidepressant-like activity in rats.
Methods:
Rats were injected with an acute single dose of A77636 (0.75, 1.5 or 3 mg/kg), a potent and selective dopamine D1-like receptor agonist. Their locomotor activity, social interactions and behavioural response to the forced swim test were analysed 30 min after the injection.
Results:
During the forced swim test, the D1 agonist dose dependently reduced the immobility while the time of bursting was increased. Social interactions were significantly increased in the animals exposed to 3 mg/kg of A77636 whereas no significant changes were measured in general motor activity.
Conclusions:
The present results provide evidence that pharmacological modulation of D1 receptor by the selective agonist A77636 induces antidepressant-like effects in rats, which encourages further studies regarding D1-specific modulation in major depressive disorder treatment.
AdmonRKaiserRHDillonDG, et al. (2017) Dopaminergic enhancement of striatal response to reward in major depression. Am J Psychiatry174: 378–386.
2.
AnyanJAmirS (2018) Too depressed to swim or too afraid to stop? A reinterpretation of the forced swim test as a measure of anxiety-like behavior. Neuropsychopharmacology43: 931–933.
3.
ArgyropoulosSVNuttDJ (2013) Anhedonia revisited: Is there a role for dopamine-targeting drugs for depression?J Psychopharmacol27: 869–877.
4.
BelujonPGraceAA (2017) Dopamine system dysregulation in major depressive disorders. Int J Neuropsychopharmacol20: 1036–1046.
5.
BertonONestlerEJ (2006) New approaches to antidepressant drug discovery: Beyond monoamines. Nat Rev Neurosci7(2): 137–151.
6.
BourinMColombelMCRedrobeJP, et al. (1998) Evaluation of efficacies of different classes of antidepressants in the forced swimming test in mice at different ages. Prog Neuro-Psychoph22: 343–351.
7.
BrunsRFMitchellSNWaffordKA, et al. (2018) Preclinical profile of a dopamine D1 potentiator suggests therapeutic utility in neurological and psychiatric disorders. Neuropharmacology128: 351–365.
8.
CadedduRIbbaMSadileA, et al. (2014) Antidepressants share the ability to increase catecholamine output in the bed nucleus of stria terminalis: A possible role in antidepressant therapy?Psychopharmacology231: 1925–1933.
9.
CarrKDKimG-Yde VacaSC (2001) Rewarding and locomotor-activating effects of direct dopamine receptor agonists are augmented by chronic food restriction in rats. Psychopharmacology154: 420–428.
10.
ChaudhuryDWalshJJFriedmanAK, et al. (2013) Rapid regulation of depression-related behaviours by control of midbrain dopamine neurons. Nature493: 532–536.
11.
ChausmerALKatzJL (2002) Comparison of interactions of D 1-like agonists, SKF 81297, SKF 82958 and A-77636, with cocaine: Locomotor activity and drug discrimination studies in rodents. Psychopharmacology159: 145–153.
12.
CiprianiAFurukawaTASalantiG, et al. (2018) Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: A systematic review and network meta-analysis. Lancet391: 1357–1366.
13.
CzéhBFuchsEWiborgO, et al. (2016) Animal models of major depression and their clinical implications. Prog Neuropsychopharmacol Biol Psychiatry64: 293–310.
14.
D’AquilaPSColluMPaniL, et al. (1994) Antidepressant-like effect of selective dopamine D1 receptor agonists in the behavioural despair animal model of depression. Eur J Pharmacol262: 107–111.
15.
de KloetERMolendijkML (2016) Coping with the forced swim stressor: Towards understanding an adaptive mechanism. Neural Plast2016: 6503162.
16.
DeNinnoMPSchoenleberRMacKenzieR, et al. (1991) A68930: A potent agonist selective for the dopamine D1 receptor. Eur J Pharmacol199: 209–219.
17.
Di ChiaraG (1999) Drug addiction as dopamine-dependent associative learning disorder. Eur J Pharmacol375: 13–30.
18.
DunlopBWNemeroffCB (2007) The role of dopamine in the pathophysiology of depression. Arch Gen Psychiatry64: 327–337.
19.
EsumiSKawasakiYNakamotoA, et al. (2013) Differential effects of nomifensine and imipramine on motivated behavior in the runway model of intracranial self-stimulation. Eur J Pharmacol720: 186–191.
20.
FriedmanAKWalshJJJuarezB, et al. (2014) Enhancing depression mechanisms in midbrain dopamine neurons achieves homeostatic resilience. Science344: 313–319.
21.
GambaranaCGhiglieriOTagliamonteA, et al. (1995) Crucial role of D1 dopamine receptors in mediating the antidepressant effect of imipramine. Pharmacol Biochem Behav50: 147–151.
22.
GoldenSACovingtonHEBertonO, et al. (2011) A standardized protocol for repeated social defeat stress in mice. Nat Protoc6: 1183–1191.
23.
GunaydinLAGrosenickLFinkelsteinJC, et al. (2014) Natural neural projection dynamics underlying social behavior. Cell157: 1535–1551.
24.
HaoJBeckJPSchausJM, et al. (2019) Synthesis and pharmacological characterization of 2-(2,6-dichlorophenyl)-1-((1S,3R)-5-(3-hydroxy-3-methylbutyl)-3-(hydroxymethyl)-1-methyl-3,4-dihydroisoquinolin-2(1H)-yl)ethan-1-one (LY3154207), a potent, subtype selective, and orally available positive allosteric modulator of the human dopamine D1 receptor. J Med Chem62: 8711–8732.
25.
HareBDShinoharaRLiuRJ, et al. (2019) Optogenetic stimulation of medial prefrontal cortex Drd1 neurons produces rapid and long-lasting antidepressant effects. Nat Commun10: 1–12.
IchikawaJMeltzerHY (1995) Effect of antidepressants on striatal and accumbens extracellular dopamine levels. Eur J Pharmacol281: 255–261.
28.
IsacsonRKullBWahlestedtC, et al. (2004) A 68930 and dihydrexidine inhibit locomotor activity and d-amphetamine-induced hyperactivity in rats: A role of inhibitory dopamine d1/5 receptors in the prefrontal cortex?Neuroscience124: 33–42.
29.
JayTMRocherCHotteM, et al. (2004) Plasticity at hippocampal to prefrontal cortex synapses is impaired by loss of dopamine and stress: Importance for psychiatric diseases. Neurotox Res6: 233–244.
30.
KesslerRCBrometEJ (2013) The epidemiology of depression across cultures. Annu Rev Public Health34: 119–138.
31.
KokkinouMAshokAHHowesOD (2018) The effects of ketamine on dopaminergic function: Meta-analysis and review of the implications for neuropsychiatric disorders. Mol Psychiatry23: 59–69.
32.
LavergneFJayTM (2010) A new strategy for antidepressant prescription. Front Neurosci4: 192.
MattaRTiessenANCholerisE (2017) The role of dorsal hippocampal dopamine D1-type receptors in social learning, social interactions, and food intake in male and female mice. Neuropsychopharmacology42: 2344–2353.
35.
MattinglyBARowlettJKLovellG (1993) Effects of daily SKF 38393, quinpirole, and SCH 23390 treatments on locomotor activity and subsequent sensitivity to apomorphine. Psychopharmacology110: 320–326.
36.
MolendijkMLde KloetER (2019) Coping with the forced swim stressor: Current state-of-the-art. Behav Brain Res364: 1–10.
37.
PizzagalliDABerrettaSWootenD, et al. (2019) Assessment of striatal dopamine transporter binding in individuals with major depressive disorder: In vivo positron emission tomography and postmortem evidence. JAMA Psychiatry76: 854–861.
38.
Plavén-SigrayPGustavssonPFardeL, et al. (2014) Dopamine D1 receptor availability is related to social behavior: A positron emission tomography study. NeuroImage102: 590–595.
39.
PorsoltRDLe PichonMJalfreM (1977) Depression: A new animal model sensitive to antidepressant treatments. Nature266: 730–732.
40.
RandrupA (1975) Mania, depression, and brain dopamine. In: Essman WB and Valzelli S (eds) Current Development in Psychopharmacology. New York: Spectrum Publications, pp. 206–248.
41.
RobertsBMSeymourPASchmidtCJ, et al. (2010) Amelioration of ketamine-induced working memory deficits by dopamine D1 receptor agonists. Psychopharmacology210: 407–418.
42.
RocherCSpeddingMMunozC, et al. (2004) Acute stress-induced changes in hippocampal/prefrontal circuits in rats: Effects of antidepressants. Cereb Cortex14: 224–229.
43.
RushAJTrivediMHWisniewskiSR, et al. (2006) Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D report. Am J Psychiatry163: 1905–1917.
44.
SampsonDWillnerPMuscatR (1991) Reversal of antidepressant action by dopamine antagonists in an animal model of depression. Psychopharmacology104: 491–495.
45.
ScheggiSDe MontisMGGambaranaC (2018) Making sense of rodent models of anhedonia. Int J Neuropsychopharmacol21: 1049–1065.
46.
SchneierFRSlifsteinMWhittonAE, et al. (2018) Dopamine release in antidepressant-naive major depressive disorder: A multimodal [11C]-(+)-PHNO positron emission tomography and functional magnetic resonance imaging study. Biol Psychiatry84: 563–573.
47.
ShutoTKuroiwaMSotogakuN, et al. (2018) Obligatory roles of dopamine D1 receptors in the dentate gyrus in antidepressant actions of a selective serotonin reuptake inhibitor, fluoxetine. Mol Psychiatr25: 1229–1244.
48.
SlatteryDACryanJF (2012) Using the rat forced swim test to assess antidepressant-like activity in rodents. Nat Protoc7: 1009–1014.
49.
StuchlikAValesK (2006) Effect of dopamine D1 receptor antagonist SCH23390 and D1 agonist A77636 on active allothetic place avoidance, a spatial cognition task. Behav Brain Res172: 250–255.
50.
SvenssonKAHaoJBrunsRF (2019) Positive allosteric modulators of the dopamine D1 receptor: A new mechanism for the treatment of neuropsychiatric disorders. Adv Pharmacol86: 273–305.
51.
TyeKMMirzabekovJJWardenMR, et al. (2013) Dopamine neurons modulate neural encoding and expression of depression-related behaviour. Nature493: 537–541.
52.
WillnerP (2016) The chronic mild stress (CMS) model of depression: History, evaluation and usage. Neur Stress6: 78–93.
53.
YadidGFriedmanA (2008) Dynamics of the dopaminergic system as a key component to the understanding of depression. Prog Brain Res172: 265–286.
54.
YamadaJSugimotoYYamadaS (2004) Involvement of dopamine receptors in the anti-immobility effects of dopamine re-uptake inhibitors in the forced swimming test. Eur J Pharmacol504: 207–211.
